Trial Profile

Dose finding crossover trial investigating the effect of dronabinol combined with acetazolamide on Apnoea Hypopnea Index (AHI) in adults with obstructive sleep apnoea (OSA)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acetazolamide/dronabinol (Primary)
Indications Sleep apnoea syndrome
Focus Proof of concept; Therapeutic Use
Sponsors Incannex Healthcare

Most Recent Events

11 Apr 2025 Results assessing the effect of a combination of acetazolamide and dronabinol (IHL-42X) at low, medium, and high doses on OSA severity, published in the Sleep
27 Jul 2022 Results presented in an Incannex Healthcare Media Release.
03 Jun 2022 Results presented in an Incannex Healthcare Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com